pfizer glp-1 news targets obesity with new once-daily danuglipron drug Pfizer just made a quiet

A meta-analysis that combined data from systematic reviews and meta-analyses came to the conclusion that there was likely no increase in the risk of diabetic retinopathy from any of the diabetes drugs.[ref] However, this is still a side effect to be aware of and talk with your doctor about your individual risk

This is a developing area of study, but it aligns with real-world reports of improved mobility and comfort during weight loss

I preferred to avoid synthetic implants, so Dr

doi: 10.1016/j.pharmthera.2006.11.007

Our team evaluates each patients medical history, current health status, and weight loss goals to determine if GLP-1 therapy is appropriate

Molecular endocrinology 27, 12341244, doi: 10.1210/me.2013-1116 (2013)